Foothills Medical Centre

Running trials

• Not yet recruiting

  Heart tEam Decision-making Assisted by Revaz AI Trial

  NCT07837765· Source

• Recruiting

  Optimized Recruitment to Drive Equitable Research in Stroke, Empowering Decision-making (ORDERed)

  NCT07576647· Source

• Not yet recruiting

  Transcranial Magnetic Stimulation for Depression in Multiple Sclerosis

  NCT07562074· Phase 1· Source

• Recruiting

  The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

  NCT06494878· Phase 3· Source

• Not yet recruiting

  Vision and Proprioception Evaluation With Robotics After Stroke

  NCT07254949· Source

• Recruiting

  Feasibility and Pilot Testing of "My Heart and CKD" Online Shared Decision Aid

  NCT06920927· Source

• Not yet recruiting

  Post-stroke REhabilitation Start Evaluation for Reducing Vascular Events

  NCT07212738· Source

• Active, not recruiting

  Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

  NCT06700343· Phase 3· Source

• Enrolling by invitation

  Testing of a System for Remote Ischemic Conditioning in Cerebral Small Vessel Disease and Pre-hospital Stroke Care

  NCT05967728· Phase 2· Source

• Recruiting

  Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples

  NCT06133374· Source

• Recruiting

  Implementation of an App-based Walking Aid Skills Training Program

  NCT05347875· Source

• Active, not recruiting

  Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

  NCT05478304· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

  NCT04770779· Phase 3· Source

• Active, not recruiting

  A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

  NCT04965493· Phase 3· Source

• Recruiting

  Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

  NCT03938987· Phase 1/2· Source

• Active, not recruiting

  SyncAV Post-Market Trial

  NCT04100148· Source

• Active, not recruiting

  AMPLATZER PFO Occluder Post Approval Study

  NCT03309332· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke5 recruiting
• Coronary artery disease2 recruiting
• Multiple sclerosis2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Depression1 recruiting
• Thyroid cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Confirm Rx Insertable Cardiac Monitor SMART Registry

  NCT03505801· Source

• Completed

  PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

  NCT03168776· Source

• Completed

  A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006· Phase 3· Source

• Completed

  Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

  NCT02168829· Phase 4· Source